Fixing the paradigm for biopharmaceutical R&D: Where to start?

Author： Milne Christopher-Paul  

Publisher： Inderscience Publishers

ISSN： 0963-6048

Source： International Journal of Biotechnology, Vol.10, Iss.5, 2008-11, pp. : 404-415

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

R&D spending and sources of funding of private US biopharmaceutical firms seeking to go public

By Williams David R   Pouder Richard W  

Journal of Commercial Biotechnology, Vol. 16, Iss. 4, 2010-10 ,pp. : 284-292

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Competitive biomedical R&D?

By Sussman P.N.  

Trends in Biotechnology, Vol. 16, Iss. 12, 1998-12 ,pp. : 528-528

Elsevier

Access to resources Recommend Favorite

Will genomics revolutionise pharmaceutical R&D?

By Noble D.  

Trends in Biotechnology, Vol. 21, Iss. 8, 2003-08 ,pp. : 333-337

Elsevier

Access to resources Recommend Favorite

Rethinking innovation in pharmaceutical R&D

By Baker Ann   Gill Jasween  

Journal of Commercial Biotechnology, Vol. 12, Iss. 1, 2005-10 ,pp. : 45-49

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Getting an insight in the determinants of new product introductions of US biopharmaceutical start-ups

By Clarysse Bart   Debackere Koen  

International Journal of Biotechnology, Vol. 3, Iss. 1-2, 2003-07 ,pp. : 33-56

Inderscience Publishers

Access to resources Recommend Favorite